Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.45 |
| ▸ | TSPO | P30536 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC5R | P33032 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047829 | 0.96 | MTNR1A (0.42) | MTNR1AMTNR1BTSPOLMNAMC4R | |
| SCHEMBL6047776 | 0.94 | MTNR1A (0.43) | MTNR1AMTNR1BTSPOLMNAPOLB | |
| SCHEMBL6047818 | 0.91 | MC4R (0.48) | MTNR1AMTNR1BMC4RMC5RMC3R | |
| SCHEMBL6047791 | 0.91 | MTNR1A (0.41) | MTNR1AMTNR1BTSPOLMNAMC4R | |
| SCHEMBL6047808 | 0.90 | KDM4E (0.43) | MTNR1AMTNR1BTSPOLMNAMC4R | |
| SCHEMBL6047772 | 0.88 | MC4R (0.43) | MTNR1AMTNR1BTSPOMC4RMC5R | |
| SCHEMBL4697988 | 0.88 | MC4R (0.46) | MTNR1AMTNR1BTSPOMC4RMC5R | |
| SCHEMBL6047881 | 0.86 | MTNR1A (0.41) | MTNR1AMTNR1BTSPO | |
| SCHEMBL6047815 | 0.85 | MTNR1A (0.43) | MTNR1AMTNR1BTSPOLMNAPOLB | |
| SCHEMBL6047887 | 0.84 | POLB (0.53) | MTNR1AMTNR1BTSPOLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | MTNR1A 799/4885MTNR1B 531/4885TSPO 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.